longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Aytu BioPharma

AYTU

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -1.58, below the reasonable range, cheaper than 90.26% of the time in the past 5 years, and the industry ranks 123/255, the industry Median -1.27.

-1.58xP/E
$2.07Stock price
$-1.31Earnings per share
-1.58xP/E
Stock price$2.07Earnings per share$-1.31

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-0.67x
Typical range
-1.21x–-0.16x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-54.04x149.86%$56.42B
BAYRYUSBayer
-24.62x--$49.67B
BAYZFUSBayer Aktiengesellschaft
-25.70x--$51.86B
VTRSUSViatris
-49.22x107.75%$20.22B
ELANUSElanco Animal Health
-55.59x129.36%$11.06B
AXSMUSAxsome Therap
-48.99x26.61%$9.39B
VREOFUSVIREO GROWTH INC
-134.31x--$9.01B
CURLFUSCuraleaf Holdings, Inc.
-146.39x--$7.62B
BLTEUSBelite Bio
-62.77x29.87%$6.43B
DFTXUSDefinium Therapeutics
-14.20x53.61%$5.03B
MANEUSVeraDermics
-46.78x97.44%$4.88B
EWTXUSEdgewise Therapeutics
-22.80x137.29%$4.50B
AMLXUSAmylyx Pharmaceuticals
-22.93x1.76%$3.49B
ELVNUSEnliven Therapeutics
-32.49x6.39%$3.44B
RGCUSRegencell Bioscience
-479.41x--$3.38B
TARSUSTarsus Pharmaceuticals
-68.93x205.82%$3.20B
MBXUSMBX Biosciences
-27.02x30.54%$2.82B
SUPNUSSupernus Pharma
-22.42x70.59%$2.46B
PHVSUSPharvaris BV
-11.04x9.52%$2.19B
BHCUSBausch Health
-1.98x307.94%$2.17B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.